Pyrotinib Maleate

马来酸吡咯替尼

Report date: 2026/05/18 20:02:07
NME

Base Information

Drug NamePyrotinib Maleate
Drug Alias Namepyrroltinib maleate吡咯替尼pyrotinib dimaleatepyrotinibPyrrolitinib Maleate +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitorsReceptor protein-tyrosine kinase erbB-4 inhibitors
TargetsReceptor protein-tyrosine kinase erbB-4Epidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[12] 
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaBreast Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2018/08/12
Country/TerritoryBelgiumUnited StatesTaiwan +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHlb Life Science Co LtdDr.Reddy's Laboratories LtdShanghai Hengrui Pharmaceutical Co Ltd +[4] 
Inactive CompaniesTongji UniversityHengrui Therapeutics IncFudan University +[4] 
Active IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsCarcinoma, Non-Small-Cell Lung +[7] 
Inactive IndicationsSolid tumoursGastrointestinal NeoplasmsBile Duct Neoplasms +[5] 

Other Information

ATC CodeL01XE
Related LinksDrugBank